STING and TLR-independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody

被引：0
|
作者：
Byrne, Katelyn T. [1 ]
Morrison, Alexander H. [2 ]
Vonderheide, Robert H. [3 ]
机构：
[1] Univ Penn, Perelman Sch Med, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 24期
关键词：
D O I：
10.1158/1538-7445.PANCA19-PR04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR04
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nonredundant roles for immune checkpoint blockade and agonistic CD40 in mediating T-cell responses in pancreatic ductal adenocarcinoma
    Morrison, Alexander H.
    Byrne, Katelyn T.
    Vonderheide, Robert H.
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Agonistic CD40 antibody combined with chemotherapy drives TLR4/MyD88 independent regression of pancreatic tumors in a T cell dependent manner
    Byrne, Katelyn T.
    Vonderheide, Robert H.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)
  • [3] The role of CD40 ligand in costimulation and T-cell activation
    Grewal, IS
    Flavell, RA
    IMMUNOLOGICAL REVIEWS, 1996, 153 : 85 - 106
  • [4] CD40 antibody as an adjuvant induces enhanced T cell responses
    Carlring, J
    Barr, TA
    McCormick, AL
    Health, AW
    VACCINE, 2004, 22 (25-26) : 3323 - 3328
  • [5] CD40 is Required For Protective T Cell Responses Against Cryptosporidium
    O'Dea, Keenan
    Hunter, Christopher A.
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [6] The CD40 agonistic antibody APX005M 'licenses' antigen presenting cells to promote tumor-specific T-cell responses
    Filbert, Erin L.
    Bjorck, Pia
    Yang, Xiaodong
    Trifan, Ovidiu C.
    CANCER RESEARCH, 2016, 76
  • [7] A combined effect of immune checkpoint inhibitors and a CD40 agonistic antibody in a pancreatic cancer mouse model
    Ichikawa, Juri
    Kawano, Kuniyuki
    Kato, Shingo
    Kurotaki, Daisuke
    Kuroishikawa, Ryo
    Kawase, Wataru
    Yoshida, Haruka
    Hiroshima, Yukihiko
    Endo, Itaru
    Maeda, Shin
    Nakajima, Atsushi
    Tamura, Tomohiko
    CANCER SCIENCE, 2024, 115 : 763 - 763
  • [8] Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
    van Hooren, Luuk
    Georganaki, Maria
    Huang, Hua
    Mangsbo, Sara M.
    Dimberg, Anna
    ONCOTARGET, 2016, 7 (31) : 50277 - 50289
  • [9] Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
    van Hooren, Luuk
    Georganaki, Maria
    Huang, Hua
    Mangsbo, Sara
    Dimberg, Anna
    CANCER RESEARCH, 2016, 76
  • [10] CD40 LIGAND-INDEPENDENT B-CELL ACTIVATION REVEALED BY CD40 LIGAND-DEFICIENT T-CELL CLONES - EVIDENCE FOR DISTINCT ACTIVATION REQUIREMENTS FOR ANTIBODY-FORMATION AND B-CELL PROLIFERATION
    LANE, P
    BURDET, C
    MCCONNELL, F
    LANZAVECCHIA, A
    PADOVAN, E
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (06) : 1788 - 1793
12345